Bambusa Therapeutics, Inc. (NASDAQ:BBTX – Get Free Report) major shareholder Salvia Investment Gmbh purchased 375,000 shares of the stock in a transaction on Monday, November 2nd. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $6,000,000.00. Following the acquisition, the insider directly owned 9,264,301 shares in the company, valued at approximately $148,228,816. This trade represents a 4.22% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Bambusa Therapeutics Price Performance
Shares of BBTX stock opened at $16.07 on Thursday. Bambusa Therapeutics, Inc. has a 52-week low of $13.60 and a 52-week high of $17.42.
About Bambusa Therapeutics
Bambusa Therapeutics, Inc is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation and fundamentally improve patient quality of life. Its pipeline includes BBT001, BBT002, BBT003 and BBT004. Bambusa Therapeutics, Inc is based in BOSTON.
Featured Articles
- Five stocks we like better than Bambusa Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Bambusa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bambusa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
